101
|
Kobayashi Y, Yuki S, Kawamoto Y, Sawada K, Miyagishima T, Ehira N, Iwanaga I, Okuda H, Tateyama M, Tsuji Y, Hatanaka K, Nakamura M, Kudo M, Fukushima H, Tagaki T, Hisai H, Koike M, Abe R, Sakata Y, Komatsu Y. 2094 Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol With Panitumumab: J-STEPP): Updated analysis of anti-tumor efficacy. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31016-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
102
|
Nakamura M, Yuki S, Nakatsumi H, Muto O, Hosokawa A, Kato T, Iwanaga I, Hatanaka K, Tsuji Y, Sato A, Eto K, Furukawa K, Okuda H, Onodera M, Fujikawa K, Kudo M, Yokoyama S, Honda T, Sakata Y, Komatsu Y. 2096 Phase II trial of Irinotecan plus S-1 (IRIS) with Cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type of metastatic colorectal cancer (mCRC): HGCSG0902 updated analysis. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31018-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
103
|
|
104
|
|
105
|
Chau I, Park J, Ryoo B, Yen C, Poon R, Pastorelli D, Blanc J, Kudo M, Pfiffer T, Hatano E, Chung H, Kubackova K, Phelip J, Brandi G, Ohkawa S, Li C, Okusaka T, Yang L, Abada P, Zhu A. 2337 Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31253-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
106
|
Hatanaka K, Yuki S, Nakatsumi H, Hosokawa A, Nakamura M, Muto O, Meguro T, Iwanaga I, Tsuji Y, Sato A, Eto K, Furukawa K, Onodera M, Tateyama M, Takahashi Y, Dazai M, Yokoyama S, Honda T, Okuda H, Kudo M, Sakata Y, Komatsu Y. P-269 Phase II trial of Irinotecan/S-1 (IRIS) with Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS WT metastatic colorectal cancer: HGCSG0902. -Comparison of administration interval in Cetuximab treatment. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv233.266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
107
|
Zhu A, Kudo M, Park J, Ryoo BY, Yen CJ, Chung HC, Baron A, Okusaka T, Poon R, Pastorelli D, Blanc JF, Flesch Pfiffer T, Kubackova K, Trojan J, Sastre J, Malfertheiner P, Peck-Radosavljevic M, Chang SC, Abada P, Yang L, Girvan A, Chau I. O-005 Ramucirumab (RAM) as second-Line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib: comprehensive results from the randomized phase III REACH study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv235.04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
108
|
|
109
|
Kudo M, Kaneda K, Yokoyama S, Nagasaka S, Taki T, Yoshida Y, Marui A, Nishiwaki N. [Adult congenital aortic coarctaion;report of a case]. Kyobu Geka 2015; 68:133-135. [PMID: 25743358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
A 63-year-old man with a history of hypertension from 20-year-old complained of dyspnea on effort. He was diagnosed as an adult congenital aortic coarctaion by computed tomography (CT). The CT showed the many collaterals from the subclavian artery, the internal thoracic artery and the intercostal artery to the descending aorta. The coarctation was totally replaced with prosthetic graft through 3rd left thoracotomy under partial cardiopulmonary bypass. The operation was successful and the postoperative course was uneventful. To avoid postoperative paradoxical hypertension, total prosthetic replacement is preferable.
Collapse
Affiliation(s)
- Masafumi Kudo
- Department of Cardiovascular Surgery, Cardiovascular Center, Nara Hospital, Kinki University Faculty of Medicine, Ikoma, Japan
| | | | | | | | | | | | | | | |
Collapse
|
110
|
Masuoka T, Nakamura T, Kudo M, Yoshida J, Takaoka Y, Kato N, Ishibashi T, Imaizumi N, Nishio M. Biphasic modulation by mGlu5 receptors of TRPV1-mediated intracellular calcium elevation in sensory neurons contributes to heat sensitivity. Br J Pharmacol 2014; 172:1020-33. [PMID: 25297838 DOI: 10.1111/bph.12962] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2014] [Revised: 09/15/2014] [Accepted: 09/26/2014] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND AND PURPOSE Elevation of glutamate, an excitatory amino acid, during inflammation and injury plays a crucial role in the reception and transmission of sensory information via ionotropic and metabotropic receptors. This study aimed to investigate the mechanisms underlying the biphasic effects of metabotropic glutamate mGlu5 receptor activation on responses to noxious heat. EXPERIMENTAL APPROACH We assessed the effects of intraplantar quisqualate, a non-selective glutamate receptor agonist, on heat and mechanical pain behaviours in mice. In addition, the effects of quisqualate on the intracellular calcium response and on membrane currents mediated by TRPV1 channels, were examined in cultured dorsal root ganglion neurons from mice. KEY RESULTS Activation of mGlu5 receptors in hind paw transiently increased, then decreased, the response to noxious heat. In sensory neurons, activation of mGlu5 receptors potentiated TRPV1-mediated intracellular calcium elevation, while terminating activation of mGlu5 receptors depressed it. TRPV1-induced currents were potentiated by activation of mGlu5 receptors under voltage clamp conditions and these disappeared after washout. However, voltage-gated calcium currents were inhibited by the mGlu5 receptor agonist, even after washout. CONCLUSIONS AND IMPLICATIONS These results suggest that, in sensory neurons, mGlu5 receptors biphasically modulate TRPV1-mediated intracellular calcium response via transient potentiation of TRPV1 channel-induced currents and persistent inhibition of voltage-gated calcium currents, contributing to heat hyper- and hypoalgesia.
Collapse
Affiliation(s)
- T Masuoka
- Department of Pharmacology, School of Medicine, Kanazawa Medical University, Uchinada, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
111
|
Pinato DJ, Karamanakos G, Arizumi T, Adjogatse D, Kim YW, Stebbing J, Kudo M, Jang JW, Sharma R. Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study. Aliment Pharmacol Ther 2014; 40:1270-81. [PMID: 25327965 DOI: 10.1111/apt.12992] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2014] [Revised: 08/27/2014] [Accepted: 09/28/2014] [Indexed: 12/19/2022]
Abstract
BACKGROUND Transarterial chemoembolisation (TACE) is a standard treatment for unresectable, intermediate stage hepatocellular carcinoma (HCC). Survival after TACE, however, can be highly variable, with no suitable biomarker predicting therapeutic outcome. The inflammation-based index (IBI) has previously been shown to independently predict overall survival (OS) in all stages of HCC. AIM To explore the prognostic ability of IBI as a predictor of survival after TACE. METHODS Baseline staging, biochemical and clinicopathological features including IBI were studied in a derivation set of 64 patients undergoing TACE for intermediate stage HCC. Dynamic changes in IBI before and after TACE were studied as predictors of survival using both a univariate and multivariate Cox regression model and further validated in two independent patient cohorts from Korea (n = 76) and Japan (n = 577). RESULTS Pre-treatment IBI predicted for OS in the derivation set (P = 0.001). Other univariate predictors of OS included radiological response to TACE (P < 0.001), pre-TACE CLIP score (P < 0.01), tumour diameter >5 cm (P = 0.05) and AFP ≥400 (P < 0.001). Normalisation of IBI post-TACE was associated with radiological response by mRECIST criteria and improved OS (P < 0.001). Normalisation of IBI remained a significant multivariate predictor of OS in both the derivation and validation sets (P < 0.001). CONCLUSIONS Normalisation of IBI after TACE is shown to be an independent predictor of survival and may be integrated into the retreatment criteria for repeat TACE in intermediate stage HCC. IBI and its dynamic changes after treatment are validated as a biomarker allowing the stratification of patients with a significant survival advantage following initial TACE.
Collapse
Affiliation(s)
- D J Pinato
- Division of Experimental Medicine, Imperial College London, Hammersmith Hospital, London, UK
| | | | | | | | | | | | | | | | | |
Collapse
|
112
|
|
113
|
Raoul J, Peck-Radosavljevic M, Lee H, Kudo M, Nakajima K, Cheng A. An International Observational Study to Assess the Use of Sorafenib After Transarterial Chemoembolization (Tace) in Patients with Hepatocellular Carcinoma (Hcc): Optimis. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu334.128] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
114
|
Muto O, Yuki S, Nakamura M, Hosokawa A, Kato T, Iwanaga I, Hatanaka K, Tsuji Y, Sato A, Eto K, Furukawa K, Okuda H, Onodera M, Fujikawa K, Kudo M, Yokoyama S, Honda T, Sakata Y, Komatsu Y. First Report of a Phase Ii Trial of Irinotecan Plus S-1 (Iris) with Cetuximab (Iris/Cet) in Pre-Treated Patients with Kras Wild Type of Metastatic Colorectal Cancer (Mcrc): Hgcsg0902. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu333.41] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
115
|
Zhu A, Ryoo B, Yen C, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung H, Baron A, Pfiffer T, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada P, Yang L, Schwartz J, Park J. Ramucirumab (Ram) As Second-Line Treatment in Patients (Pts) with Advanced Hepatocellular Carcinoma (Hcc) Following First-Line Therapy with Sorafenib: Results from the Randomized Phase III Reach Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu438.16] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
116
|
Kang YK, Yau T, Park JW, Boucher E, Lim H, Poon R, Lee TY, Obi S, Chan S, Qin S, Kim R, Tang J, Valota O, Chakrabarti D, Kudo M. Randomised Study of Axitinib (Axi) Plus Best Supportive Care (Bsc) Versus Placebo (Pbo) Plus Bsc in Patients with Advanced Hepatocellular Carcinoma (Hcc) Following Prior Antiangiogenic Therapy. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu438.17] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
117
|
Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, de Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract 2014; 68:609-17. [PMID: 24283303 PMCID: PMC4265239 DOI: 10.1111/ijcp.12352] [Citation(s) in RCA: 185] [Impact Index Per Article: 18.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma [HCC] and Of its treatment with sorafeNib) is a global, prospective, non-interventional study undertaken to evaluate the safety of sorafenib in patients with unresectable HCC in real-life practice, including Child-Pugh B patients who were excluded from clinical trials. METHODS Patients with unresectable HCC, for whom the decision to treat with sorafenib, based on the approved label and prescribing guidelines, had been taken by their physician, were eligible for inclusion. Demographic data and disease/medical history were recorded at entry. Sorafenib dosing and adverse events (AEs) were collected at follow-up visits. The second interim analysis was undertaken when ~1500 treated patients were followed up for ≥ 4 months. RESULTS Of the 1571 patients evaluable for safety, 61% had Child-Pugh A status and 23% Child-Pugh B. The majority of patients (74%) received the approved 800 mg initial sorafenib dose, regardless of Child-Pugh status; however, median duration of therapy was shorter in Child-Pugh B patients. The majority of drug-related AEs were grade 1 or 2, and the most commonly reported were consistent with previous reports. The incidence and nature of drug-related AEs were broadly similar across Child-Pugh, Barcelona Clinic Liver Cancer (BCLC) and initial dosing subgroups, and consistent with the overall population. CONCLUSIONS Consistent with the first interim analysis, overall safety profile and dosing strategy are similar across Child-Pugh subgroups. Safety findings also appear comparable irrespective of initial sorafenib dose or BCLC stage. Final analyses in > 3000 patients are ongoing.
Collapse
Affiliation(s)
- R Lencioni
- Division of Diagnostic Imaging and Intervention, Pisa University Hospital and School of Medicine, Pisa, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
118
|
|
119
|
Iwanaga I, Yuki S, Fukushima H, Sogabe S, Kudo M, Hatanaka K, Kato K, Sonoda N, Sakata Y, Komatsu Y. Randomized Study to Explore Indisetron for the Prevention of Acute-Onset Diarrhea, Nausea, Vomiting with IRIS/FOLFIRI. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt460.144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
120
|
Nouso K, Miyahara K, Uchida D, Kuwaki K, Izumi N, Omata M, Ichida T, Kudo M, Ku Y, Kokudo N, Sakamoto M, Nakashima O, Takayama T, Matsui O, Matsuyama Y, Yamamoto K. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. Br J Cancer 2013; 109:1904-7. [PMID: 24008659 PMCID: PMC3790188 DOI: 10.1038/bjc.2013.542] [Citation(s) in RCA: 108] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2013] [Revised: 08/02/2013] [Accepted: 08/14/2013] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND The efficacy of hepatic arterial infusion chemotherapy for the treatment of advanced hepatocellular carcinoma (HCC) remains unclear. METHODS The outcome of 476 patients with HCC who underwent hepatic arterial infusion chemotherapy with 5-fluorouracil and cisplatin (HAIC) were compared with 1466 patients who did not receive active therapy. RESULTS A survival benefit of the therapy after adjusting for known risk factors was observed (hazard ratio, 0.48; 95% CI, 0.41-0.56; P<0.0001). In propensity score-matched analysis (n=682), median survival time was longer for patients who underwent chemotherapy (14.0 months) than for patients who did not receive active treatment (5.2 months, P<0.0001). CONCLUSION For advanced HCC, HAIC is considered to be an effective treatment.
Collapse
Affiliation(s)
- K Nouso
- Department of Molecular Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama-city, Okayama, 700-8558, Japan
| | - K Miyahara
- Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama-city, Okayama, 700-8558, Japan
| | - D Uchida
- Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama-city, Okayama, 700-8558, Japan
| | - K Kuwaki
- Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama-city, Okayama, 700-8558, Japan
| | - N Izumi
- Department of Gastroenterology, Musashino Red Cross Hospital, Musashino-city, Tokyo, 180-8610, Japan
| | - M Omata
- Yamanashi Prefectural Hospital Organization, Kofu-city, Yamanashi, 400-8506, Japan
| | - T Ichida
- Department of Gastroenterology, Juntendo University Shizuoka Hospital, Izunokuni-city, Shizuoka, 410-2295, Japan
| | - M Kudo
- Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Sayama-city, Osaka, 589-8511, Japan
| | - Y Ku
- Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe-city, Hyogo, 650-0017, Japan
| | - N Kokudo
- Department of Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, Japan
| | - M Sakamoto
- Department of Pathology, Keio University School of Medicine, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - O Nakashima
- Department of Pathology, Kurume University School of Medicine, Kurume-city, Fukuoka, 830-0011, Japan
| | - T Takayama
- Department of Digestive Surgery, Nihon University School of Medicine, Itabashi-ku, Tokyo, 173-8610, Japan
| | - O Matsui
- Department of Radiology, Kanazawa University Graduate School of Medical Science, Kanazawa-city, Ishikawa, 920-8641, Japan
| | - Y Matsuyama
- Department of Biostatistics, School of Public Health, University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, Japan
| | - K Yamamoto
- Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama-city, Okayama, 700-8558, Japan
| | - the Liver Cancer Study Group of Japan
- Department of Molecular Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama-city, Okayama, 700-8558, Japan
- Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama-city, Okayama, 700-8558, Japan
- Department of Gastroenterology, Musashino Red Cross Hospital, Musashino-city, Tokyo, 180-8610, Japan
- Yamanashi Prefectural Hospital Organization, Kofu-city, Yamanashi, 400-8506, Japan
- Department of Gastroenterology, Juntendo University Shizuoka Hospital, Izunokuni-city, Shizuoka, 410-2295, Japan
- Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Sayama-city, Osaka, 589-8511, Japan
- Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe-city, Hyogo, 650-0017, Japan
- Department of Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, Japan
- Department of Pathology, Keio University School of Medicine, Shinjuku-ku, Tokyo, 160-8582, Japan
- Department of Pathology, Kurume University School of Medicine, Kurume-city, Fukuoka, 830-0011, Japan
- Department of Digestive Surgery, Nihon University School of Medicine, Itabashi-ku, Tokyo, 173-8610, Japan
- Department of Radiology, Kanazawa University Graduate School of Medical Science, Kanazawa-city, Ishikawa, 920-8641, Japan
- Department of Biostatistics, School of Public Health, University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, Japan
| |
Collapse
|
121
|
|
122
|
|
123
|
Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsøe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, Chen MH, Clevert DA, Correas JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leen ELS, Mattrey RF, Moriyasu F, Solbiati L, Weskott HP, Xu HX. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med 2013; 34:11-29. [PMID: 23129518 DOI: 10.1055/s-0032-1325499] [Citation(s) in RCA: 210] [Impact Index Per Article: 19.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Initially, a set of guidelines for the use of ultrasound contrast agents was published in 2004 dealing only with liver applications. A second edition of the guidelines in 2008 reflected changes in the available contrast agents and updated the guidelines for the liver, as well as implementing some non-liver applications. Time has moved on, and the need for international guidelines on the use of CEUS in the liver has become apparent. The present document describes the third iteration of recommendations for the hepatic use of contrast enhanced ultrasound (CEUS) using contrast specific imaging techniques. This joint WFUMB-EFSUMB initiative has implicated experts from major leading ultrasound societies worldwide. These liver CEUS guidelines are simultaneously published in the official journals of both organizing federations (i.e., Ultrasound in Medicine and Biology for WFUMB and Ultraschall in der Medizin/European Journal of Ultrasound for EFSUMB). These guidelines and recommendations provide general advice on the use of all currently clinically available ultrasound contrast agents (UCA). They are intended to create standard protocols for the use and administration of UCA in liver applications on an international basis and improve the management of patients worldwide.
Collapse
Affiliation(s)
- M Claudon
- Department of Pediatric Radiology, INSERM U947, Centre Hospitalier Universitaire de Nancy and Université de Lorraine, Vandoeuvre, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
124
|
Kudo M. Japan's Successful Model of Nationwide Hepatocellular Carcinoma Surveillance Highlighting the Urgent Need for Global Surveillance. Liver Cancer 2012; 1:141-3. [PMID: 24159578 PMCID: PMC3760465 DOI: 10.1159/000342749] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
|
125
|
Noguchi E, Omuro Y, Kudo M, Shimoyama T, Sasaki E, Okamoto R, Maeda Y, Horiguchi S, Hishima T, Sasaki T. Acute Megakaryocytic Leukemia Associated with Primary Mediastinal Germ Cell Tumor: A Case Report. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32478-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
126
|
Komatsu Y, Yuki S, Kawamoto Y, Hayashi H, Kato T, Hosokawa A, Iwanaga I, Muto O, Hatanaka K, Nakamura M, Tsuji Y, Tateyama M, Fukushima H, Kudo M, Sakata Y. Safety Report of a Phase II Trial of Irinotecan Plus S-1 (Iris) with Cetuximab in Pre-Treated Patients with KRAS Wild Type of Metastatic Colorectal Cancer: HGCSG0902. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32205-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
127
|
Yuki S, Komatsu Y, Nakatsumi H, Kobayashi Y, Takeuchi S, Sogabe S, Miyagishima T, Kato T, Hatanaka K, Nakamura M, Kudo M, Akakura N, Sonoda N, Munakata M, Sakata Y. Updated Analysis: Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients with Metastatic Colorectal Cancer: Hokkaido Gastrointestinal Cancer Study Group (HGCSG) Trial. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32186-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
128
|
|
129
|
Shimoi T, Sasaki E, Kudo M, Shimoyama T, Omuro Y, Okamoto R, Maeda Y, Sasaki T. The Impact of Performance Status at Diagnosis on Progression-Free Survival After Second-Line Chemotherapy in Unfavorable-Risk Cancer of Unknown Primary Patients. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33724-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
130
|
Bronowicki J, Ye S, Kudo M, Marrero J, Venook A, Nakajima K, Lencioni R. Gideon (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma [HCC] and of Its Treatment with Sorafenib [SOR]) 2nd Interim Analysis (IA): Subgroup Analysis by Disease Etiology. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33283-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
131
|
Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Ladrón de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Cihon F, Heldner S, Marrero JA. First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study. Int J Clin Pract 2012; 66:675-83. [PMID: 22698419 DOI: 10.1111/j.1742-1241.2012.02940.x] [Citation(s) in RCA: 94] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
AIMS Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON), a global, non-interventional, surveillance study, aims to evaluate the safety of sorafenib in all patients with unresectable hepatocellular carcinoma (uHCC) under real-life practice conditions, particularly Child-Pugh B patients, who were not well represented in clinical trials. METHODS Treatment decisions are determined by each physician according to local prescribing guidelines and clinical practice. Patients with uHCC who are candidates for systemic therapy, and for whom a decision has been made to treat with sorafenib, are eligible for inclusion. Demographic data and medical and disease history are recorded at entry. Sorafenib dosing and adverse events (AEs) are collected throughout the study. RESULTS From January 2009 to April 2011, >3000 patients from 39 countries were enrolled. The prespecified first interim analysis was conducted when the initial approximately 500 treated patients had been followed up for ≥4 months; 479 were valid for safety evaluation. Preplanned subgroup analyses indicate differences in patient characteristics, disease aetiology and previous treatments by region. Variation in sorafenib dosing by specialty are also observed; Child-Pugh status did not appear to influence the starting dose of sorafenib. The type and incidence of AEs was consistent with findings from previous clinical studies. AE profiles were comparable between Child-Pugh subgroups. DISCUSSION The GIDEON study is generating a large, robust database from a broad population of patients with uHCC. First interim analyses have shown global and regional differences in patient characteristics, disease aetiology and practice patterns. Subsequent planned analyses will allow further evaluation of early trends.
Collapse
Affiliation(s)
- R Lencioni
- Division of Diagnostic Imaging and Intervention, Pisa University Hospital and School of Medicine, Pisa, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
132
|
Kudo M. Welcome to the first issue of liver cancer. Liver Cancer 2012; 1:1. [PMID: 24159566 PMCID: PMC3747535 DOI: 10.1159/000339015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
|
133
|
Hagiwara S, Kudo M, Nagai T, Inoue T, Ueshima K, Nishida N, Watanabe T, Sakurai T. Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma. Br J Cancer 2012; 106:1997-2003. [PMID: 22596232 PMCID: PMC3388555 DOI: 10.1038/bjc.2012.145] [Citation(s) in RCA: 82] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Hepatocellular carcinoma (HCC) ranks as the third leading cause of cancer deaths worldwide. While sorafenib, a multikinase inhibitor targeting the Raf/extracellular signal-regulated protein kinase (ERK) pathway, has been shown recently to provide a survival advantage to patients with advanced HCC, a predictive biomarker has not been developed. We studied whether c-Jun N-terminal kinase (JNK), which promotes liver carcinogenesis in mice, affects therapeutic response to sorafenib in HCC patients. METHODS We collected pathological specimens from 39 patients with advanced HCC before starting sorafenib treatment, and measured JNK activity in HCCs. RESULTS In patients treated with sorafenib, the expression of phospho-c-Jun in HCC, as a read out of JNK activity, was significantly higher (P<0.001) in the non-responder group than in the responder group. c-Jun N-terminal kinase activation in HCC was associated with a decreased time to progression and a poor overall survival (P=0.0028 and P=0.0008, respectively). CONCLUSION In addition, JNK activity was significantly correlated with CD133 expression level. Correspondingly, high expression level of CD133 was linked to a poor response to sorafenib. Furthermore, D-JNKi, a specific JNK inhibitor, reduced the growth of xenografted CD133(+) cells in athymic mice. In conclusion, JNK activation was positively correlated with CD133 expression level and inversely correlated with the therapeutic response to sorafenib, suggesting that JNK activity may be considered as a new predictive biomarker for response to sorafenib treatment.
Collapse
Affiliation(s)
- S Hagiwara
- Department of Gastroenterology and Hepatology, Kinki University, Osaka-Sayama, Japan
| | | | | | | | | | | | | | | |
Collapse
|
134
|
Geschwind J, Lencioni R, Marrero J, Venook A, Ye S, Nakajima K, Kudo M. Abstract No. 196: Worldwide trends in locoregional therapy (LRT) for hepatocellular carcinoma (HCC): 2nd interim analysis (IA; 1500 patients [pts]) of the GIDEON (global investigation of therapeutic decisions in HCC and of its treatment with sorafenib) study. J Vasc Interv Radiol 2012. [DOI: 10.1016/j.jvir.2011.12.244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
135
|
Kushikata T, Yoshida H, Kudo M, Kudo T, Kudo T, Hirota K. Role of coerulean noradrenergic neurones in general anaesthesia in rats. Br J Anaesth 2011; 107:924-9. [DOI: 10.1093/bja/aer303] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
136
|
Chung H, Watanabe T, Kudo M, Chiba T. Correlation between hyporesponsiveness to Toll-like receptor ligands and liver dysfunction in patients with chronic hepatitis C virus infection. J Viral Hepat 2011; 18:e561-7. [PMID: 21914077 DOI: 10.1111/j.1365-2893.2011.01478.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Hepatitis C virus (HCV)-associated antigens, such as the core and nonstructural antigens, activate host innate immune systems via Toll-like receptors (TLRs). We previously showed that chronic exposure to the core antigen induces hyporesponsiveness to TLR ligands in antigen-presenting cells via activation of TLR2 and that stimulation with TLR ligands results in impaired IL-6 production by peripheral blood monocytes from HCV-infected patients. In the present study, peripheral blood mononuclear cells (PBMCs) isolated from patients with chronic HCV or hepatitis B virus (HBV) infection were stimulated with TLR ligands to determine the production of IL-6 and IL-8 and to identify the clinical parameters associated with hyporesponsiveness to TLR ligands in patients with chronic HCV infection. The results showed that pro-inflammatory cytokine responses to TLR ligands were suppressed in PBMCs isolated from HCV-infected, but not HBV-infected, patients. The reduced cytokine responses to TLR ligands seen in HCV-infected patients correlated with platelet counts and serum prothrombin time levels. In contrast, there was no correlation between TLR-induced cytokine responses and serum levels of core antigen. Thus, hyporesponsiveness to TLR ligands in HCV-infected patients is correlated with liver dysfunction. In conclusion, both host factors and viral factors may be involved in the generation of hyporesponsiveness to TLR ligands in patients with chronic HCV infection.
Collapse
Affiliation(s)
- H Chung
- Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Osaka, Japan
| | | | | | | |
Collapse
|
137
|
Lencioni R, Venook A, Marrero J, Kudo M, Ye S, Nakajima K, Cihon F. 6500 ORAL Second Interim Results of the GIDEON (Global Investigation of Therapeutic DEcisions in HCC and of Its Treatment With SorafeNib) Study – Barcelona-Clinic Liver Cancer (BCLC) Stage Subgroup Analysis. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71811-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
138
|
Shimogiri T, Nishida N, Kudo M, Niwa K, Nishibori M, Kinoshita K, Okamoto S, Maeda Y, Tokunaga K, Yasue H. Genetic relationships between Japanese native and commercial breeds using 70 chicken autosomal SNP genotypes by the DigiTag2 assay. Anim Genet 2011; 43:98-103. [PMID: 22221031 DOI: 10.1111/j.1365-2052.2011.02206.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Recently, single nucleotide polymorphisms (SNPs) have been used to identify genes or genomic regions responsible for economic traits, including genetic diseases in domestic animals, and to examine genetic diversity of populations. In this study, we genotyped 70 chicken autosomal SNPs using DigiTag2 assay to understand the genetic structure of the Japanese native chicken breeds Satsumadori and Ingie, and the relationship of these breeds with other established breeds, Rhode Island Red (RIR), commercial broiler and layer. Five breeds, each consisting of approximately 20 chickens, were subjected to the assay, revealing the following: Average expected heterozygosities of broiler, Satsumadori, RIR, layer and Ingie were 0.265, 0.254, 0.244, 0.179 and 0.176, respectively. Phylogenetic analysis using the concatenated 70 autosomal SNP genotypes distinguished all chickens and formed clusters of chickens belonging to the respective breeds. In addition, the 2-D scatter plot of the first two principal components was consistent with the phylogenic tree. Taken together with the pairwise F(st) distances, broiler and RIR were closely positioned near each other, while Ingie was positioned far from the other breeds. Structure analysis revealed that the probable number of genetic clusters (K) was six and four with maximum likelihood and ΔK values, respectively. The clustering with maximum likelihood revealed that, in addition to the clustering of the other five breeds, the Satsumadori was subdivided into two genetic clusters. The clustering with ΔK value indicated that the broiler and Rhode Island Red were assigned to the same genetic cluster.
Collapse
Affiliation(s)
- T Shimogiri
- Faculty of Agriculture, Kagoshima University, Kagoshima, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
139
|
Ueshima K, Kudo M, Tanaka M, Kumada T, Sakurai T, Chung H, Hagiwara S, Minami Y, Inoue T, Yada N, Kitai S, Takita M, Hayaishi S. Phase I study of sorafenib in combination with low-dose cisplatin and fluorouracil intra-arterial infusion chemotherapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e14563] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
140
|
Affiliation(s)
- K Kamata
- Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan
| | | | | | | | | | | |
Collapse
|
141
|
Cheng A, Kang Y, Lin D, Park J, Kudo M, Qin S, Omata M, Pitman Lowenthal SW, Lanzalone S, Yang L, Lechuga M, Raymond E. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4000] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
142
|
Marrero JA, Lencioni R, Kudo M, Ye S, Nakajima K, Cihon F, Venook AP. Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) second interim analysis in more than 1,500 patients: Clinical findings in patients with liver dysfunction. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4001] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
143
|
Kudo M, Izumi N, Kokudo N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Makuuchi M. Improved survival in patients with hepatocellular carcinoma over 30 years in Japan: Analysis of nationwide prospective registry of 148,161 patients. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
144
|
Yuki S, Nakatsumi H, Tateyama M, Uehata Y, Kudo M, Kato K, Miyagishima T, Uebayashi M, Asaka M, Komatsu Y. The optimal dose period of indisetron tablets for preventing chemotherapy-induced nausea and vomiting (CINV) induced by mFOLFOX6: An exploratory trial HGCSG0703. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
589 Background: Indisetron is a 5-HT3 receptor antagonist which shows also 5-HT4 antagonistic activity, that had approved in 2004 by Japan's PMDA. There are no recommendations of prophylactic regimens for preventing nausea and vomiting induced by FOLFOX therapy. To explore the optimal dose period of indisetron tablets during mFOLFOX6, we designed the study to compare the antiemetic efficacy and safety of 3-day regimen of indisetron with a single dose regimen. Methods: Advanced colorectal cancer patients who were treated with mFOLFOX6 (+/- bevacizumab) as first-line chemotherapy were enrolled in this study. They were randomly assigned to Group A (3-day of indisetron) or Group B (a single dose of indisetron). Dexamethazone (8mg) was also administered intravenously in both groups before administering of oxaliplatin. The follow-up period was 5 days from the start of chemotherapy. The primary endpoint was complete protection from vomiting, and secondary endpoints were complete protection from nausea, no use of rescue therapy, and severe adverse events. Results: Of 45 patients enrolled in this trial, 42 (93.3%) were assessable. The proportions of patients with complete protection from vomiting were 85.7% in Group A, and 81.0% in Group B (p=1.000; Fisher's exact test). The proportions of patients with complete protection from nausea were 47.6% in each group (p=1.000; chi-square test). The no rescue therapy rates were 66.7% in Group A, and 57.1% in Group B (p=0.525; chi-square test). No severe adverse events were observed in both groups. Conclusions: We suggested that the efficacy of a single dose of indisetron might be equivalent of 3-day regimen for preventing from nausea and vomiting induced by mFOLFOX6. [Table: see text]
Collapse
Affiliation(s)
- S. Yuki
- Department of Gastroenterology, Hokkaido University School of Medicine, Sapporo, Japan; Department of Internal Medicine, Tomakomai Nissho Hospital, Tomakomai, Japan; Department of Gastroenterology, Tomakomai City Hospital, Tomakomai, Japan; Department of Gastroenterology, Sapporo Hokuyu Hospital, Sapporo, Japan; Department of Internal Medicine, Iwamizawa Municipal General Hospital, Iwamizawa, Japan; Department of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan; Department of Gastroenterology,
| | - H. Nakatsumi
- Department of Gastroenterology, Hokkaido University School of Medicine, Sapporo, Japan; Department of Internal Medicine, Tomakomai Nissho Hospital, Tomakomai, Japan; Department of Gastroenterology, Tomakomai City Hospital, Tomakomai, Japan; Department of Gastroenterology, Sapporo Hokuyu Hospital, Sapporo, Japan; Department of Internal Medicine, Iwamizawa Municipal General Hospital, Iwamizawa, Japan; Department of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan; Department of Gastroenterology,
| | - M. Tateyama
- Department of Gastroenterology, Hokkaido University School of Medicine, Sapporo, Japan; Department of Internal Medicine, Tomakomai Nissho Hospital, Tomakomai, Japan; Department of Gastroenterology, Tomakomai City Hospital, Tomakomai, Japan; Department of Gastroenterology, Sapporo Hokuyu Hospital, Sapporo, Japan; Department of Internal Medicine, Iwamizawa Municipal General Hospital, Iwamizawa, Japan; Department of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan; Department of Gastroenterology,
| | - Y. Uehata
- Department of Gastroenterology, Hokkaido University School of Medicine, Sapporo, Japan; Department of Internal Medicine, Tomakomai Nissho Hospital, Tomakomai, Japan; Department of Gastroenterology, Tomakomai City Hospital, Tomakomai, Japan; Department of Gastroenterology, Sapporo Hokuyu Hospital, Sapporo, Japan; Department of Internal Medicine, Iwamizawa Municipal General Hospital, Iwamizawa, Japan; Department of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan; Department of Gastroenterology,
| | - M. Kudo
- Department of Gastroenterology, Hokkaido University School of Medicine, Sapporo, Japan; Department of Internal Medicine, Tomakomai Nissho Hospital, Tomakomai, Japan; Department of Gastroenterology, Tomakomai City Hospital, Tomakomai, Japan; Department of Gastroenterology, Sapporo Hokuyu Hospital, Sapporo, Japan; Department of Internal Medicine, Iwamizawa Municipal General Hospital, Iwamizawa, Japan; Department of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan; Department of Gastroenterology,
| | - K. Kato
- Department of Gastroenterology, Hokkaido University School of Medicine, Sapporo, Japan; Department of Internal Medicine, Tomakomai Nissho Hospital, Tomakomai, Japan; Department of Gastroenterology, Tomakomai City Hospital, Tomakomai, Japan; Department of Gastroenterology, Sapporo Hokuyu Hospital, Sapporo, Japan; Department of Internal Medicine, Iwamizawa Municipal General Hospital, Iwamizawa, Japan; Department of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan; Department of Gastroenterology,
| | - T. Miyagishima
- Department of Gastroenterology, Hokkaido University School of Medicine, Sapporo, Japan; Department of Internal Medicine, Tomakomai Nissho Hospital, Tomakomai, Japan; Department of Gastroenterology, Tomakomai City Hospital, Tomakomai, Japan; Department of Gastroenterology, Sapporo Hokuyu Hospital, Sapporo, Japan; Department of Internal Medicine, Iwamizawa Municipal General Hospital, Iwamizawa, Japan; Department of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan; Department of Gastroenterology,
| | - M. Uebayashi
- Department of Gastroenterology, Hokkaido University School of Medicine, Sapporo, Japan; Department of Internal Medicine, Tomakomai Nissho Hospital, Tomakomai, Japan; Department of Gastroenterology, Tomakomai City Hospital, Tomakomai, Japan; Department of Gastroenterology, Sapporo Hokuyu Hospital, Sapporo, Japan; Department of Internal Medicine, Iwamizawa Municipal General Hospital, Iwamizawa, Japan; Department of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan; Department of Gastroenterology,
| | - M. Asaka
- Department of Gastroenterology, Hokkaido University School of Medicine, Sapporo, Japan; Department of Internal Medicine, Tomakomai Nissho Hospital, Tomakomai, Japan; Department of Gastroenterology, Tomakomai City Hospital, Tomakomai, Japan; Department of Gastroenterology, Sapporo Hokuyu Hospital, Sapporo, Japan; Department of Internal Medicine, Iwamizawa Municipal General Hospital, Iwamizawa, Japan; Department of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan; Department of Gastroenterology,
| | - Y. Komatsu
- Department of Gastroenterology, Hokkaido University School of Medicine, Sapporo, Japan; Department of Internal Medicine, Tomakomai Nissho Hospital, Tomakomai, Japan; Department of Gastroenterology, Tomakomai City Hospital, Tomakomai, Japan; Department of Gastroenterology, Sapporo Hokuyu Hospital, Sapporo, Japan; Department of Internal Medicine, Iwamizawa Municipal General Hospital, Iwamizawa, Japan; Department of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan; Department of Gastroenterology,
| |
Collapse
|
145
|
Venook AP, Lencioni R, Marrero JA, Kudo M, Nakajima K, Ye S. First interim results of the global investigation of therapeutic decisions in hepatocellular carcinoma (HCC) and of its treatment with sorafenib (GIDEON) study: Use of sorafenib (Sor) by oncologists and nononcologists in the management of HCC. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.157] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
157 Background: GIDEON is an ongoing, global, prospective, non-interventional registry study of patients (pts) with unresectable HCC (uHCC) receiving Sor under real-life practice settings. From January 2009 to September 2010, over 2,200 pts have been enrolled from 32 countries. Per protocol, the first planned interim analysis was triggered when 500 enrolled pts were followed for at least 4 mos; the primary safety and efficacy results were reported in October 2010. A preplanned subset analysis of treatment patterns across MD specialities is reported here. Methods: Demographics, medical, disease and treatment history are recorded at enrolment; Sor dose, concomitant treatments, performance status, liver function are noted at follow-up. Standard efficacy measures and adverse events (AEs) are captured. Preplanned subanalysis by MD specialty was conducted. Results: Of the 141 treating MDs, 69 (49%) were hepatologists/gastroenterologists (Hep/GIs), 55 (39%) were medical oncologists (Oncs) and 17 (12%) were other specialties. Descriptive statistics of differences in pts' HCC stage, Sor treatment and AEs by the main specialties are shown for the 479 pts evaluable for safety (Table). Conclusions: Interim data from the GIDEON study suggests differential use of Sor by MD specialties. It appears that Oncs tend to treat with lower doses of Sor and for a somewhat shorter duration than Hep/GIs. If these data persist, it will be important to explore the reasons for these differences in Sor usage between Oncs and Hep/GIs and potential impact on patient outcomes. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. P. Venook
- University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA; Pisa University School of Medicine, Pisa, Italy; University of Michigan, Ann Arbor, MI; Kinki University School of Medicine, Osaka, Japan; Bayer HealthCare Pharmaceuticals, Montville, NJ; Zhongshan Hospital, Fudan University, Shanghai, China
| | - R. Lencioni
- University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA; Pisa University School of Medicine, Pisa, Italy; University of Michigan, Ann Arbor, MI; Kinki University School of Medicine, Osaka, Japan; Bayer HealthCare Pharmaceuticals, Montville, NJ; Zhongshan Hospital, Fudan University, Shanghai, China
| | - J. A. Marrero
- University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA; Pisa University School of Medicine, Pisa, Italy; University of Michigan, Ann Arbor, MI; Kinki University School of Medicine, Osaka, Japan; Bayer HealthCare Pharmaceuticals, Montville, NJ; Zhongshan Hospital, Fudan University, Shanghai, China
| | - M. Kudo
- University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA; Pisa University School of Medicine, Pisa, Italy; University of Michigan, Ann Arbor, MI; Kinki University School of Medicine, Osaka, Japan; Bayer HealthCare Pharmaceuticals, Montville, NJ; Zhongshan Hospital, Fudan University, Shanghai, China
| | - K. Nakajima
- University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA; Pisa University School of Medicine, Pisa, Italy; University of Michigan, Ann Arbor, MI; Kinki University School of Medicine, Osaka, Japan; Bayer HealthCare Pharmaceuticals, Montville, NJ; Zhongshan Hospital, Fudan University, Shanghai, China
| | - S. Ye
- University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA; Pisa University School of Medicine, Pisa, Italy; University of Michigan, Ann Arbor, MI; Kinki University School of Medicine, Osaka, Japan; Bayer HealthCare Pharmaceuticals, Montville, NJ; Zhongshan Hospital, Fudan University, Shanghai, China
| |
Collapse
|
146
|
Eguchi S, Kanematsu T, Arii S, Omata M, Kudo M, Sakamoto M, Takayasu K, Makuuchi M, Matsuyama Y, Monden M. Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Br J Surg 2011; 98:552-7. [PMID: 21267990 DOI: 10.1002/bjs.7393] [Citation(s) in RCA: 68] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/16/2010] [Indexed: 12/18/2022]
Abstract
BACKGROUND High recurrence rates after liver resection with curative intent for hepatocellular carcinoma (HCC) remain a problem. The characterization of long-term survivors without recurrence after liver resection may help improve the therapeutic strategy for HCC. METHODS A nationwide Japanese database was used to analyse 20 811 patients with HCC who underwent liver resection with curative intent. RESULTS The 10-year recurrence-free survival rate after liver resection for HCC with curative intent was 22.4 per cent. Some 281 patients were recurrence-free after more than 10 years. The HCCs measured less than 5 cm in 83.2 per cent, a single lesion was present in 91.7 per cent, and a simple nodular macroscopic appearance was found in 73.3 per cent of these patients; histologically, most HCCs showed no vascular invasion or intrahepatic metastases. Multivariable analysis revealed tumour differentiation as the strongest predictor of death from recurrent HCC within 5 years. CONCLUSION Long-term recurrence-free survival is possible after liver resection for HCC, particularly in patients with a single lesion measuring less than 5 cm with a simple nodular appearance and low tumour marker levels.
Collapse
Affiliation(s)
- S Eguchi
- Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
147
|
Kato N, Kudo M. Simulation of fragmentation of arginine molecule aggregate by quantum molecular dynamics for TOF-SIMS spectral analysis. SURF INTERFACE ANAL 2011. [DOI: 10.1002/sia.3394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
148
|
Affiliation(s)
- Y Umehara
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kinki University School of Medicine, Osaka-Sayama, Japan
| | | | | |
Collapse
|
149
|
Lencioni R, Marrero J, Venook A, Ye SL, Kudo M. Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. Int J Clin Pract 2010; 64:1034-41. [PMID: 20642705 PMCID: PMC2905618 DOI: 10.1111/j.1742-1241.2010.02414.x] [Citation(s) in RCA: 62] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Hepatocellular carcinoma (HCC) is a complicated condition influenced by multiple confounding factors, making optimum patient management extremely challenging. Ethnicity, stage at diagnosis, comorbidities and tumour morphology affect outcomes and vary from region to region, and there is no common language to assess patient prognosis and make treatment recommendations. Despite recent efforts to reduce the incidence of HCC, most patients present with unresectable disease. Non-surgical treatments include ablation, transarterial chemoembolisation and the multikinase inhibitor, sorafenib, but their effects in all patient subgroups are not known and further information is needed to optimise the use of these treatments. AIMS The Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with SorafeNib (GIDEON) study (ClinicalTrials.gov identifier NCT00812175; http://clinicaltrials.gov/) is an ongoing global, prospective, non-interventional study of patients with unresectable HCC who are eligible for systemic therapy and for whom the decision has been taken to treat with sorafenib under real-life practice conditions. The aim of this study is to evaluate the safety and efficacy of sorafenib in different subgroups, especially Child-Pugh B where data are limited. DISCUSSION This study will recruit 3000 patients from > 40 countries and follow them for approximately 5 years to compile a large and robust database of information that will be used to analyse local, regional and global differences in baseline characteristics, disease aetiology, treatment practice patterns and treatment outcomes, with a view to improve the knowledge base used to guide physician treatment decisions and to improve patient outcomes.
Collapse
Affiliation(s)
- R Lencioni
- Division of Diagnostic Imaging and Intervention, Department of Liver Transplantation, Hepatology and Infectious Diseases, Pisa University School of Medicine, Cisanello Hospital, Pisa, Italy.
| | | | | | | | | |
Collapse
|
150
|
Kushikata T, Yoshida H, Kudo M, Kudo T, Hirota K. Changes in plasma orexin A during propofol–fentanyl anaesthesia in patients undergoing eye surgery. Br J Anaesth 2010; 104:723-7. [DOI: 10.1093/bja/aeq098] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|